IBD Pharm Flashcards
1
Q
Sulfasalazine
A
- treatment for ULCERATIVE COLITIS
- 5-ASA (inhibits production of PG and LT from arachadonic path)
2
Q
Mesalamine
A
- treatment for ULCERATIVE COLITIS
- 5-ASA (inhibits production of PG and LT from arachadonic path)
3
Q
Olsalazine
A
- treatment for MAINTENANCE OF REMISSION FOR ULCERATIVE COLITIS
- 5-ASA (inhibits production of PG and LT from arachadonic path)
4
Q
Balsalazine
A
- treatment for ACTIVE DZ ULCERATIVE COLITIS
- 5-ASA (inhibits production of PG and LT from arachadonic path)
5
Q
Tofacitinib
A
- treatment for ULCERATIVE COLITIS
- Janus Kinase (JAK) Inhibitor (prevents phosphorylation)
6
Q
Ustekinumab
A
- treatment for BOTH ULCERATIVE COLITIS AND CHROHN DISEASE
- IL-12/IL-23 Inhibitor (block p40 s/u of IL)
- risk of reactivating TB
7
Q
Adalimumab
A
- treatment for BOTH ULCERATIVE COLITIS AND CHROHN DISEASE
- TNF-α Inhibitor
- risk of reactivating TB
8
Q
Golimumab
A
- treatment for ULCERATIVE COLITIS
- TNF-α Inhibitor
- risk of reactivating TB
9
Q
Certolizumab
A
- treatment for CHROHN DISEASE
- TNF-α Inhibitor
- risk of reactivating TB
10
Q
Infliximab
A
- treatment for:
- severe ULCERATIVE COLITIS
- moderate CHROHN DISEASE - TNF-α Inhibitor
- risk of reactivating TB
11
Q
Vedolizumab
A
- treatment for BOTH ULCERATIVE COLITIS AND CHROHN DISEASE
- α-4β7 Integrin Inhibitor (inhibit cell adhesion)
- risk of PML and infection
- require close monitoring with TOUCH program
12
Q
Natalizumab
A
- treatment for CHROHN DISEASE
- α-4β1 and α-4β7 Integrin Inhibitor (inhibit cell adhesion)
- risk of PML and infection
- require close monitoring with TOUCH program
